Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1077-1085 , September 2009

High-Dose Iodine-131-Metaiodobenzylguanidine with Haploidentical Stem Cell Transplantation and Posttransplant Immunotherapy in Children with Relapsed/Refractory Neuroblastoma

  • Jacek Toporski

      Affiliations

    • Department of Pediatric Oncology, University Hospital, Lund, Sweden
    • Corresponding Author InformationCorrespondence and reprint requests: Jacek Toporski, MD, Department of Pediatric Oncology, University Hospital, SE-221 85 Lund, Sweden.
    • ,
  • Michael Garkavij

      Affiliations

    • Department of Oncology, University Hospital, Lund, Sweden
    • ,
  • Jan Tennvall

      Affiliations

    • Department of Oncology, University Hospital, Lund, Sweden
    • ,
  • Ingrid Øra

      Affiliations

    • Department of Pediatric Oncology, University Hospital, Lund, Sweden
    • ,
  • Katarina Sjögreen Gleisner

      Affiliations

    • Department of Radiation Physics, University Hospital, Lund, Sweden
    • ,
  • Josefina H. Dykes

      Affiliations

    • Blood Center, University Hospital, Lund, Sweden
    • Division of Hematology and Transfusion Medicine, Institute of Laboratory Medicine, Lund University, Lund, Sweden
    • ,
  • Stig Lenhoff

      Affiliations

    • Department of Hematology, University Hospital, Lund, Sweden
    • ,
  • Gunnar Juliusson

      Affiliations

    • Department of Hematology, University Hospital, Lund, Sweden
    • Stem Cell Center, Lund University, Lund, Sweden
    • ,
  • Stefan Scheding

      Affiliations

    • Department of Hematology, University Hospital, Lund, Sweden
    • Stem Cell Center, Lund University, Lund, Sweden
    • ,
  • Dominik Turkiewicz

      Affiliations

    • Department of Pediatric Oncology, University Hospital, Lund, Sweden
    • Department of Pediatric Hematology and Oncology, Medical University, Wrocław, Poland
    • ,
  • Albert N. Békássy

      Affiliations

    • Department of Pediatric Oncology, University Hospital, Lund, Sweden

Received 22 March 2009 ,Accepted 7 May 2009.

References 

  1. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol. 1999;17:3221–3225
  2. Matthay KK. Neuroblastoma: biology and therapy. Oncology. 1997;11:1857–1866discussion 1869-1872, 1875
  3. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054–1060
  4. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142–2149
  5. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24:500–506
  6. Ladenstein R, Lasset C, Hartmann O, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1994;14:37–46
  7. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997;33:2130–2135
  8. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol. 1994;12:2382–2389
  9. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 2001;27:777–783
  10. Lang P, Greil J, Bader P, et al. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis. 2004;33:281–287
  11. Bethge WA, Faul C, Einsele H, Lang P, Handgretinger R, Kanz L. Haploidentical allogeneic haematopoietic cell transplantation in adults using dosereduced conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Bone Marrow Transplant. 2005;35:S107
  12. Lang P, Pfeiffer M, Muller I, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr. 2006;218:321–326
  13. Inoue M, Nakano T, Yoneda A, et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant. 2003;32:103–106
  14. Koscielniak E, Gross-Wieltsch U, Treuner J, et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J Clin Oncol. 2005;23:242–244
  15. Miflin G, Charley C, Stainer C, Anderson S, Hunter A, Russell N. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol. 1996;95:345–348
  16. Holig K, Platzbecker U, Rutt C. Side effects of peripheral blood progenitor cell (PBPC) mobilization and collection using G-CSF (lenograstim)-long term follow-up of 1125 unrelated donors (abstract). Blood. 2003;102:ASH 2003 abstract book
  17. Dykes JH, Toporski J, Juliusson G, et al. Rapid and effective CD3 T-cell depletion with a magnetic cell sorting program to produce peripheral blood progenitor cell products for haploidentical transplantation in children and adults. Transfusion. 2007;47:2134–2142
  18. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol. 2006;18:586–591
  19. Ahrens N, Tormin A, Paulus M, et al. Mesenchymal stem cell content of human vertebral bone marrow. Transplantation. 2004;78:925–929
  20. Handgretinger R, Chen X, Pfeiffer M, et al. Feasability and outcome of reduced intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci. 2007;1106:279–289
  21. Brodeur GM, Maris JM. Neuroblastoma. In:  Pizzo PA,  Poplack DG editor. Principles and Practice of Pediatric Oncology. 4th Edition. Philadephia, PA: Lippincott-Raven; 2001;p. 895–937
  22. Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol. 1992;10:323–329
  23. Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In:  Ries LAG,  Smith MA,  Gurney JG editor. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99–4649. Bethesda, MD: National Cancer Institute, SEER Program; 1999;
  24. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173
  25. Rosti G, Ferrante P, Ledermann J, et al. High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol. 2002;41:129–140
  26. Matthay KK, Kushner BH. Treatment of relapsed and refractory neuroblastoma. In:  Cheung NK,  Cohn SL editor. Neuroblastoma. Berlin Heidelberg: Springer; 2005;p. 193–212
  27. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994;84:380–383
  28. Handgretinger R, Leung W, Ihm K, Lang P, Klingebiel T, Niethammer D. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?. Br J Cancer. 2003;88:1874–1877
  29. Ross AA. Minimal residual disease in solid tumor malignancies: a review. J Hematother. 1998;7:9–18
  30. Corrias MV, Haupt R, Carlini B, et al. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res. 2006;12:5680–5685
  31. Prigione I, Corrias MV, Airoldi I, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci. 2004;1028:69–80
  32. Wolfl M, Jungbluth AA, Garrido F, et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54:400–406
  33. Raffaghello L, Prigione I, Bocca P, et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005;24:4634–4644
  34. Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 2005;228:155–161
  35. Castriconi R, Dondero A, Cilli M, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother. 2007;56:1733–1742
  36. Neal ZC, Imboden M, Rakhmilevich AL, et al. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother. 2004;53:41–52
  37. Gopas J, Itzhaky D, Segev Y, et al. Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells. Cancer Immunol Immunother. 1992;34:313–320
  38. De Geer A, Kiessling R, Levitsky V, Levitskaya J. Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion. J Immunol. 2006;177:7540–7550
  39. Cinatl J, Cinatl J, Vogel JU, et al. Persistent human cytomegalovirus infection induces drug resistance and alteration of programmed cell death in human neuroblastoma cells. Cancer Res. 1998;58:367–372
  40. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62:3347–3350
  41. Söderberg-Nauclér C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol. 2008;41:218–223
  42. Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet. 2002;360:1557–1563
  43. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170:998–1002

 Financial disclosure: See Acknowledgments on page 1084.

PII: S1083-8791(09)00233-X

doi: 10.1016/j.bbmt.2009.05.007

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1077-1085 , September 2009

Article Tools

* Image Usage & Resolution